Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86042 | 1.00 | KDR (0.43) | KDRTGFBR1ULK1PSMB8IKBKB | |
| SCHEMBL86044 | 0.88 | BRAF (0.41) | KDRTGFBR1RAF1 | |
| SCHEMBL76916 | 0.84 | PARP1 (0.39) | JAK2JAK3BUB1RAF1 | |
| SCHEMBL85793 | 0.84 | PARP1 (0.39) | JAK2JAK3BUB1RAF1 | |
| SCHEMBL76915 | 0.84 | PARP1 (0.39) | JAK2JAK3BUB1RAF1 | |
| SCHEMBL76954 | 0.83 | PARP1 (0.39) | KDRJAK2JAK3BUB1RAF1 | |
| SCHEMBL86072 | 0.83 | PARP1 (0.39) | KDRJAK2JAK3BUB1RAF1 | |
| SCHEMBL78166 | 0.83 | PARP1 (0.39) | KDRJAK2JAK3BUB1RAF1 | |
| SCHEMBL78051 | 0.83 | PARP1 (0.39) | KDRJAK2JAK3BUB1RAF1 | |
| SCHEMBL78165 | 0.83 | PARP1 (0.39) | KDRJAK2JAK3BUB1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129396-B2 | 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129396-B2 | 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2010036873-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | TELIK, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081653-A1 | 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors | MAP3K2, MAP4K2, MAP3K12 | KDR 615/4885TGFBR1 3765/4885ULK1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.